IDH1 Mutation Impacts DNA Repair Through ALKBH2 Rendering Glioblastoma Cells Sensitive to Artesunate

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Isocitrate dehydrogenase 1 and 2 (IDH1/2) enzymes are crucial for metabolic processes and DNA repair.
• Mutations in IDH1/2 are common in gliomas, leading to 2-hydroxyglutarate (2-HG) production and altered cellular functions.
• IDH1/2-mutated gliomas have a better prognosis, potentially due to impaired DNA repair, such as by ALKBH2.

Purpose of the Study:

• To investigate the effect of artesunate (ART) on glioma cells with wild-type and mutated IDH1.
• To determine the role of 2-hydroxyglutarate (2-HG) and ALKBH2 in the cellular response to ART.
• To explore the therapeutic potential of ART in IDH1/2-mutated gliomas.

Main Methods:

• Utilized isogenic glioblastoma cell lines with inducible IDH1 wild-type or mutant expression.
• Treated cells with varying doses of artesunate (ART).
• Assessed ART sensitivity in cells treated with 2-HG and in ALKBH2 knockout cells.

Main Results:

• Artesunate's cell-killing effect was enhanced in glioblastoma cells expressing mutant IDH1 (R132H).
• 2-hydroxyglutarate (2-HG) mimicked the effect of mutant IDH1, ameliorating artesunate cytotoxicity.
• ALKBH2 knockout sensitized glioblastoma cells to artesunate's cytotoxic effects.

Conclusions:

• ALKBH2 protects against the anticancer effects of artesunate.
• IDH1/2 mutations sensitize gliomas to artesunate through an ALKBH2-dependent mechanism.
• Artesunate shows promise for treating IDH1/2-mutated cancers, potentially in combination therapies.